Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Court for the District of New Jersey on behalf of shareholders of Integra LifeSciences Holdings Corporation who purchased shares between March 11, 2019 and September 27, 2023.
Integra and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On May 23, 2023, the Company disclosed that it was recalling all medical device products made at its Boston Facility between March 1, 2018 and May 22, 2023 due to a deviation from good manufacturing practices in testing for bacterial endotoxin and the release of products with higher levels of endotoxins, as well as an extended halt on production. As a result, the Company lowered its 2Q 2023 revenue guidance by 6% and adjusted earnings per diluted share by 26% and disclosed an expected $22 million impairment charge due to the inventory write-off.
On this news, shares of Integra plummeted $10.24 per share, or 20%, from a closing price of $50.72 per share on May 22, 2023, to a closing price of $40.48 per share on May 23, 2023.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until November 13, 2023 to request that the court appoint them lead plaintiff.